Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Sponsor: Alliance for Clinical Trials in Oncology
A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Alliance for Clinical Trials in Oncology and has accumulated 11 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
May 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — May 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance for Clinical Trials in Oncology
- Cancer and Leukemia Group B
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .